Literature DB >> 236061

Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhoea.

P Beumont, J Bruwer, B Pimstone, A Vinik, W Utian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 236061     DOI： 10.1192/bjp.126.3.285

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


× No keyword cloud information.
  6 in total

1.  Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.

Authors:  S R Tollin
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

Review 2.  Hypothesis: bromocriptine lacks intrinsic dopamine receptor stimulating properties.

Authors:  D M Jackson; O F Jenkins
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

3.  Bromocriptine and psychosis: a literature review.

Authors:  A Boyd
Journal:  Psychiatr Q       Date:  1995

Review 4.  Use of bromocriptine in hyperprolactinaemic anovulation and related disorders.

Authors:  S Franks
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

Review 5.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Drugs and prolactin.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2008       Impact factor: 4.107
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.